S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$83.44
+1.29 (+1.57 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$82.40
Now: $83.44
$84.98
50-Day Range
$63.98
MA: $77.09
$85.37
52-Week Range
$19.51
Now: $83.44
$86.75
Volume656,129 shs
Average Volume875,402 shs
Market Capitalization$8.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals logo

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

672nd out of 1,928 stocks

Pharmaceutical Preparations Industry

336th out of 774 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Employees232

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.99 million
Book Value$4.51 per share

Profitability

Net Income$-84,550,000.00

Miscellaneous

Market Cap$8.57 billion
Next Earnings Date2/4/2021 (Confirmed)
OptionableOptionable
$83.44
+1.29 (+1.57 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

How has Arrowhead Pharmaceuticals' stock been impacted by Coronavirus?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARWR shares have increased by 192.2% and is now trading at $83.44.
View which stocks have been most impacted by COVID-19
.

Is Arrowhead Pharmaceuticals a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arrowhead Pharmaceuticals?

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Arrowhead Pharmaceuticals' CEO?

1,428 employees have rated Arrowhead Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Arrowhead Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How can I listen to Arrowhead Pharmaceuticals' earnings call?

Arrowhead Pharmaceuticals will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings data on Sunday, November, 22nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.34 by $0.82. The biotechnology company had revenue of $7.63 million for the quarter, compared to the consensus estimate of $85.13 million. Arrowhead Pharmaceuticals had a negative net margin of 96.09% and a negative return on equity of 17.37%.
View Arrowhead Pharmaceuticals' earnings history
.

What price target have analysts set for ARWR?

12 brokerages have issued 1-year price objectives for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $98.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $76.62 in the next twelve months. This suggests that the stock has a possible downside of 8.2%.
View analysts' price targets for Arrowhead Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 52, Pay $2.22M)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 55, Pay $685.85k)
  • Mr. Patrick O'Brien, Gen. Counsel & Corp. Sec. (Age 57, Pay $683.54k)
  • Dr. Bruce D. Given, Advisor (Age 67, Pay $1.35M)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone, VP of Investor Relations
  • Mr. Howard Lovy, Director of Communications
  • Dr. James C. Hamilton, Head of Clinical Devel. & VP
  • Dr. Mark Seefeld, Head of Toxicology & VP (Age 67)

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Columbus Circle Investors (0.13%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.02%), Pacer Advisors Inc. (0.01%), Crossmark Global Holdings Inc. (0.01%) and Arden Trust Co (0.00%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Columbus Circle Investors, Crossmark Global Holdings Inc., Arden Trust Co, and State of Alaska Department of Revenue. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Palladiem LLC, Fulton Bank N.A., and Louisiana State Employees Retirement System.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $83.44.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $8.57 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.